Special Section on Transporters in Drug Disposition and Pharmacokinetic Prediction

Sandwich-Cultured Hepatocytes for Mechanistic Understanding of Hepatic Disposition of Parent Drugs and Metabolites by Transporter–Enzyme Interplay[§]

Norikazu Matsunaga, Yukina Fukuchi, Haruo Imawaka, and Ikumi Tamai

Pharmacokinetic Research Laboratories, Ono Pharmaceutical Co., Ltd., Tsukuba, Japan (N.M. Y.F., H.I.); Department of Membrane Transport and Biopharmaceutics, Faculty of Pharmaceutical Sciences, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, Kanazawa, Japan (I.T.)

Received October 29, 2017; accepted January 17, 2018

ABSTRACT

Functional interplay between transporters and drug-metabolizing enzymes is currently one of the hottest topics in the field of drug metabolism and pharmacokinetics. Uptake transporter-enzyme interplay is important to determine intrinsic hepatic clearance based on the extended clearance concept. Enzyme and efflux transporter interplay, which includes both sinusoidal (basolateral) and canalicular efflux transporters, determines the fate of metabolites formed in the liver. As sandwich-cultured hepatocytes (SCHs) maintain metabolic activities and form a canalicular network, the whole interplay between uptake and efflux transporters and drug-metabolizing enzymes can be investigated

simultaneously. In this article, we review the utility and applicability of SCHs for mechanistic understanding of hepatic disposition of both parent drugs and metabolites. In addition, the utility of SCHs for mimicking species-specific disposition of parent drugs and metabolites in vivo is described. We also review application of SCHs for clinically relevant prediction of drug-drug interactions caused by drugs and metabolites. The usefulness of mathematical modeling of hepatic disposition of parent drugs and metabolites in SCHs is described to allow a quantitative understanding of an event in vitro and to develop a more advanced model to predict in vivo disposition.

Introduction

In drug development, pharmacokinetics play a central role in understanding the relationship of exposure with efficacy and safety. Research work in drug metabolism and pharmacokinetics has focused on optimization of absorption, distribution, metabolism, and excretion properties to give an adequate pharmacokinetics profile of a new chemical entity (NCE). These efforts have significantly reduced the failure rate of projects in clinical development due to pharmacokinetics

issues from approximately 40% in the 1990s to <10% in the 2000s (Kennedy, 1997; Frank and Hargreaves, 2003). Accumulated information on drug-metabolizing enzymes and transporters has contributed significantly to advances in drug metabolism and pharmacokinetics research. We have now entered a new era, with the goal of understanding transporter-mediated disposition (Hillgren et al., 2013), determining intrinsic clearance of metabolically stable NCEs (Di and Obach, 2015), and evaluating systemic exposure of metabolites (Yu et al., 2010).

The liver is one of the key organs for these activities because it is a major clearance organ of NCEs via metabolism and biliary excretion. In addition to these two processes, uptake and efflux on the sinusoidal (basolateral) membrane of the liver are involved in hepatic intrinsic

<https://doi.org/10.1124/dmd.117.079236>.

[§]This article has supplemental material available at dmd.aspetjournals.org.

ABBREVIATIONS: BA, bile acid; BCRP, breast cancer resistance protein; BDG, bilirubin diglucuronide; BEI, biliary excretion index; BMG, bilirubin monoglucuronide; BSEP, bile salt export pump; CAN, candesartan; CCX, candesartan cilexetil; CDF, 5(6)-carboxy-2',7'-dichlorofluorescein; CDFDA, 5(6)-carboxy-2',7'-dichlorofluorescein diacetate; CL_{int,bile}, intrinsic biliary excretion clearance; CL_{int,bile,app}, apparent CL_{int,bile}; CL_{int,H}, hepatic intrinsic clearance; CPD-0801, 2,5-bis (5-amidino)-2-pyridyl furan; CP-I, coproporphyrin-I; CPD-0868, 2,5-bis [5-(N-methoxyamidino)-2-pyridyl] furan; CsA, cyclosporin A; DDI, drug-drug interaction; DM-4103, tolaptan; ECM, extracellular matrix; E₂, estradiol; E17G, estradiol 17 β -D-glucuronide; MPA, mycophenolic acid; MPAG, mycophenolic acid phenyl-glucuronide; MRP, multidrug resistance-associated protein; NCE, new chemical entity; NTCP, sodium taurocholate cotransporting polypeptide; OATP, organic anion-transporting polypeptide; P450, cytochrome P450; P-gp, P-glycoprotein; QTLI, quantitative time-lapse imaging; Ro 64-1056, 4-(1-hydroxy-2-methylpropan-2-yl)-N-[5-(2-hydroxyphenoxy)-2-pyrimidin-2-yl-6-(1,1,2,2-tetradeuterio-2-hydroxyethoxy)pyrimidin-4-yl]benzenesulfonamide; Ro 47-8634, 4-tert-butyl-N-[6-(2-hydroxyethoxy)-5-(2-hydroxyphenoxy)-2-(pyrimidin-2-yl)pyrimidin-4-yl]benzene-1-sulfonamide (bosentan); Ro 48-5033, 4-(2-hydroxy-1,1-dimethyl-ethyl)-N-[6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-[2,2#1]; [bipyrimidinyl-4-yl]-benzenesulfonamide; ; SCH, sandwich-cultured hepatocyte; SN-38, 7-ethyl-10-hydroxycamptothecin; tauro-nor-THCA-24-DBD, N-(24-[7-(4-N,N-dimethylaminosulfonyl-2,1,3-benzoxadiazole)]amino-3 α ,7 α ,12 α -trihydroxy-27-nor-5 β -cholestan-26-oyl)-2'-aminoethanesulfonate; TCA, taurocholate; UGT, UDP-glucuronosyltransferase.

clearance ($CL_{int,H}$) based on the extended clearance concept (Varma and El-Kattan, 2016), which is calculated by eq. 1.

$$CL_{int,H} = (PS_{int,active} + PS_{int,passive}) \times \frac{(CL_{int,met} + CL_{int,bile})}{(PS_{int,passive} + PS_{int,efflux} + CL_{int,met} + CL_{int,bile})} \quad (1)$$

$PS_{int,active}$, $PS_{int,passive}$, and $PS_{int,efflux}$ are intrinsic clearances via uptake transport, passive diffusion, and basolateral efflux transport, respectively. $CL_{int,met}$ and $CL_{int,bile}$ represent intrinsic metabolic and biliary excretion clearances. When $CL_{int,met} + CL_{int,bile}$ is larger than $PS_{int,passive}$ and $PS_{int,efflux}$, $CL_{int,H}$ becomes close to $PS_{int,active}$ and $PS_{int,passive}$ and is mainly determined by active uptake transporter-mediated intrinsic clearance. In contrast, under a condition where $PS_{int,passive} + PS_{int,efflux}$ is considerable to $CL_{int,met} + CL_{int,bile}$, $CL_{int,H}$ is governed by all the individual processes (Varma and El-Kattan, 2016).

Accordingly, characterization of the four processes is important to understand functional interplay between transporters and drug-metabolizing enzymes. For instance, metabolism in the liver is a major clearance route of atorvastatin, repaglinide, and saquinavir. However, these drugs are not only substrates of cytochrome P450 (P450), but also substrates of organic anion-transporting polypeptides (OATPs). In the case of such dual substrates, uptake transporter-enzyme interplay has to be considered to determine $CL_{int,H}$, and identification of the rate-determining process is important for prediction of drug disposition in vivo (Parker and Houston, 2008; Watanabe et al., 2010; Varma et al., 2013; Varma and El-Kattan, 2016) (Fig. 1).

The extended clearance concept is basic and applies to all NCEs, meaning that the equation is applicable to metabolites as well as parent drugs. The U.S. Food and Drug Administration's guidance for safety

testing of drug metabolites, called the MIST guidance and ICH-M3(R2), first issued in 2008 and 2009, respectively (CDER and CBER, 2010; CDER, 2016), have had a significant impact on drug discovery and development in pharmaceutical companies because further evaluation of circulating metabolites is required in both nonclinical species and humans. Unlike the parent drug, a metabolite is generally formed intracellularly in the liver. Therefore, there has to be greater emphasis on enzyme–efflux transporter interplay in the liver to understand hepatic disposition and systemic exposure of metabolites mechanistically (Fig. 1).

Several in vitro test systems have been established to determine enzyme- and transporter-mediated intrinsic clearance. For instance, microsomes are commonly used for determining intrinsic metabolic clearance of NCEs by P450 enzymes and UDP-glucuronosyltransferases (UGTs) (Obach, 1999; Naritomi et al., 2001; Kilford et al., 2009; Gill et al., 2012). Cell lines or *Xenopus* oocytes overexpressing drug-associated transporters are useful for investigation of the involvement and kinetics of transporters (Tamai et al., 2001; Nozawa et al., 2005; Nakakariya et al., 2008; Tzvetkov et al., 2013). Among established in vitro systems, isolated and/or cultured hepatocytes have been widely recognized as a holistic and reliable model to investigate both enzyme- and transporter-mediated intrinsic clearances and their interplay (Soars et al., 2007; Chiba et al., 2009; Di et al., 2012), although large interindividual variability of enzyme and transporter activities is observed among donors. Several forms of hepatocytes are used to investigate enzyme- and transporter-mediated hepatic disposition, including suspended and plated hepatocytes, cocultures, and three-dimensional models (Tetsuka et al., 2017), but sandwich-cultured hepatocytes (SCHs) are the focus of this article because of their unique feature of allowing evaluation of the whole interplay between uptake and efflux transporters and drug-metabolizing enzymes.

Fig. 1. Transporter-enzyme interplay in the liver.

Characteristics of SCHs

The sandwich culture system has been developed and established over two decades (Dunn et al., 1989; LeCluyse et al., 1994, 1999; Tuschl et al., 2009; Sharma et al., 2010). As the name suggests, SCHs are hepatocytes cultivated between extracellular matrices (ECMs). Commercial ECMs, Matrigel and Geltrex, are generally used to overlay hepatocytes attached to collagen I-coated plates. Compared with a conventional culture model (monolayer-plated hepatocytes), the sandwich culture system allows hepatocytes to maintain their polarity, morphology, and liver-specific activities, such as albumin secretion (Dunn et al., 1989; LeCluyse et al., 1994; Blaheta et al., 1998; Tuschl et al., 2009). There is debate about changes of metabolic enzyme activities in SCHs during culture, with some studies showing similar metabolic activities in suspended hepatocytes and SCHs (Lau et al., 2002; Treijtel et al., 2005), whereas others show lower activities in SCHs (Kern et al., 1997; Slaus et al., 2001; Kienhuis et al., 2007; Matsunaga et al., 2013). The transition of metabolic enzyme activities during culture depends on the conditions of the hepatocytes (fresh or cryopreserved) and ECM and differs among isoenzymes and species.

One of the greatest advantages of SCHs is the ability to form bile canaliculi with the entire array of transport proteins involved in biliary excretion, and the bile canaliculi networks can be disrupted by calcium/magnesium depletion in buffer (B-CLEAR Technology; Qualyst Transporter Solutions, Durham, NC) (Brouwer et al., 2013). This unique feature has allowed investigation of biliary excretion by canalicular transporters, including P-glycoprotein (P-gp), multidrug resistance-associated protein 2 (MRP2), breast cancer resistance protein (BCRP), and bile salt export pump (BSEP), in SCHs by modulation of the calcium/magnesium level in buffer.

The major parameters obtained from SCHs are the biliary excretion index (BEI) and $CL_{\text{int,bile}}$, which are calculated by eqs. 2 and 3, respectively.

$$\text{BEI (\%)} = \frac{\text{Accumulation}_{\text{cell+bile}} - \text{Accumulation}_{\text{cell}}}{\text{Accumulation}_{\text{cell+bile}}} \times 100 \quad (2)$$

$$CL_{\text{int,bile}} = \frac{\text{Accumulation}_{\text{cell+bile}} - \text{Accumulation}_{\text{cell}}}{\text{Intracellular AUC}} \quad (3)$$

BEI is a qualitative index of biliary excretion and is not correlated with *in vivo* extent of biliary excretion (% of dose) (Fukuda et al., 2008; Tetsuka et al., 2014a). A large interindividual variability is observed in intracellular/bile canalicular accumulations; however, BEI is relatively comparable among individual donors, especially in compounds showing high BEI (Fukuda et al., 2008; Matsunaga et al., 2014). In addition, the experiments using the same donor suggest a good reproducibility of accumulations and BEIs (Matsunaga et al., 2015, 2016).

$CL_{\text{int,bile}}$ in SCHs represents the biliary excretion clearance from hepatocytes to bile canaliculi and is correlated with the *in vivo* liver exposure-based $CL_{\text{int,bile}}$ (Nakakariya et al., 2012). Apparent $CL_{\text{int,bile}}$ ($CL_{\text{int,bile,app}}$) calculated from the extracellular concentration in buffer can also be used for prediction of the *in vivo* plasma exposure-based $CL_{\text{int,bile}}$ with correction for protein binding, pairs of transporters involved in uptake and biliary excretion, and a large scaling factor (up to 300-fold) to bridge the *in vitro* to *in vivo* gap (Fukuda et al., 2008; Nakakariya et al., 2012; Zou et al., 2013).

Zou et al. (2013) suggest several reasons why a larger scaling factor is required for compounds with low $CL_{\text{int,bile,app}}$. For instance, a measurement error for compounds with low biliary excretion and/or high protein binding leads to poor prediction. In addition, to achieve good response on measurement for compounds with low uptake to hepatocytes, those are often incubated at high concentration in protein-free buffer. The high concentration in the buffer may partially saturate uptake and/or efflux

transporters in SCHs, leading to underestimation. They also suggest that addition of serum protein or plasma/serum itself to the buffer can reduce the prediction error because serum protein serves just as a drug solubilizer and does not remarkably change hepatic uptake of lipophilic compounds with high protein binding.

In addition to excretion across the canalicular membranes, SCHs allow investigation of basolateral uptake and efflux transport processes. The major drug-associated uptake transporters in human liver are OATPs, sodium taurocholate cotransporting polypeptide (NTCP), and organic cation transporter 1 (OCT1) (Fig. 2), and all of these transporters function in human SCHs. The activities of uptake transporters in SCHs depend on the culture condition and species, and are usually similar to or less than those in other forms of hepatocytes (Hoffmaster et al., 2005; Bi et al., 2006; De Bruyn et al., 2011; Jacobsen et al., 2011; Kotani et al., 2011; Tchapanian et al., 2011). Comparisons of uptake transporter activities between SCHs and hepatocytes in suspension are summarized in Table 1.

A recent meta-analysis showed that the levels of OATP1B1 and OATP1B3 do not differ significantly between human liver tissue and human SCHs, but that there is a difference for OATP2B1 (Badée et al., 2015). In contrast, protein levels of major rat Oatps, Oatp1a1, Oatp1a4, and Oatp1b2, are significantly lower in SCHs than those in liver tissues (Ishida et al., 2018). MRP3 and MRP4 expressed on the basolateral membrane of hepatocytes are involved in the efflux of numerous endogenous and exogenous compounds.

A vesicle-based system is suitable to investigate involvement and interaction of efflux transporters; however, it is still unclear if vesicle-based data can be used to predict sinusoidal efflux and biliary excretion clearance, and the magnitude of the interaction (Brouwer et al., 2013). In contrast, SCHs retain both basolateral and canalicular efflux transporter networks, and the functional involvement of MRP3 and/or MRP4 has been reported in efflux of rosuvastatin, enalaprilat, and mycophenolic acid phenyl-glucuronide (MPAG) in SCHs (Pfeifer et al., 2013a; Ferslew et al., 2014; Matsunaga et al., 2015). Enalaprilat and MPAG are formed in the liver and undergo translocation into the systemic circulation. These findings highlight that comprehensive analyses of efflux processes is essential to predict drug disposition *in vivo*, especially for metabolites because intracellular formation of a metabolite is the first step, followed by excretion into the bloodstream and/or bile (enzyme–efflux transporter interplay).

In addition, a metabolite is usually more hydrophilic and less membrane permeable than a parent compound (Pang et al., 1984; de Lannoy and Pang, 1987) and involvement of non-P450 enzymes, especially UGTs, has increased because of the effort to escape P450-mediated metabolism and improve metabolic stability during drug discovery and development (Argikar et al., 2016). Therefore, efflux transporters may have a major role in transport of a metabolite from the liver to the blood and/or bile. Therefore, SCHs are a suitable model to investigate the hepatic disposition of both a parent drug (mainly uptake transporter–enzyme interplay) and an intracellularly formed metabolite (mainly enzyme–efflux transporter interplay). On the other hand, in TR^- rats, genetically MRP2-deficient rats, glucuronidation activities are higher than those in wild-type Wistar rats (Westley et al., 2008; Yang and Brouwer, 2014), suggesting UGT activities in TR^- rat SCHs are higher than those in wild-type Wistar rat SCHs. Accordingly, it should be noted that functional change of canalicular transporters may lead to functional change of drug-metabolizing enzymes.

Prediction of Species Differences in Hepatic Disposition of Metabolites

Differences in biliary excretion of drugs have been reported across species (Grime and Paine, 2013). Molecular weight is one of determinant

Fig. 2. Major drug-associated transporters in human liver. OATPs (OATP1B1, OATP1B3, and OATP2B1), NTCP, organic cation transporter 1 (OCT1), and organic anion transporter OAT2 are major uptake transporters in human liver. MRP3, MRP4, and heteromer organic solute transporters OST- α/β are expressed on the same basolateral membrane and are involved in efflux from hepatocytes to the bloodstream. BCRP, BSEP, P-gp, and MRP2 are major canalicular efflux transporters involved in biliary excretion (Hillgren et al., 2013).

of substrates for canalicular efflux transporters BCRP and MRP2, with different molecular weight thresholds in rats and humans (Kato et al., 2008; Choi et al., 2009; Yang et al., 2009). For anionic compounds, a molecular weight higher than 400 and 475 g/mol is assumed the cutoff value in rats and humans, respectively, whereas no threshold molecular weight is identified for cationic and neutral compounds either in rats or humans.

In addition, recent quantitative structure–activity relationship analyses have shown some features of canalicular transporters for substrate recognition. For instance, P-gp substrates are bulky, highly branched, and good electron acceptors. BCRP substrates contain a large, positively charged surface and have aromatic rings. MRP2 substrates are flexible in addition to having a large polar and hydrophilic surface area. P-gp and BCRP are more associated with explicit aromaticity-related features, whereas MRP2 is predominately associated with hydrophilicity-related properties (Aniceto et al., 2016).

Because a metabolite, especially a conjugated metabolite, has a higher molecular mass and hydrophilicity than the parent drug, the metabolite is more likely to be a substrate of a canalicular efflux transporter, as shown in Table 2. Some reports have indicated that basolateral and canalicular efflux in SCHs are correlated with *in vivo* excretion of metabolites into urine or bile. For instance, paroxetine is mainly metabolized in the liver and excreted in the form of metabolites. M1-glucuronide, a major metabolite of paroxetine, is mainly excreted into bile after oral administration in rats. In humans, in contrast, M1-sulfate and M1-

glucuronide are major metabolites and are mainly excreted in urine (Haddock et al., 1989; Kaye et al., 1989). In rat SCHs, M1-glucuronide was found to be the main metabolite, with minimal levels of other metabolites, including M1-sulfate. In contrast, similar levels of M1-glucuronide and M1-sulfate were observed in human SCHs. The BEIs of intracellularly formed M1-glucuronide were ~50.9% in rats and ~15.6% in humans, respectively (Matsunaga et al., 2013), which is consistent with the main elimination routes of M1-glucuronide in rats and humans.

Similar data have been reported for mycophenolic acid (MPA), which is mainly metabolized to MPAG in the liver (Shipkova et al., 2001). In rats, MPAG is excreted in bile and urine, whereas MPAG is mainly excreted in urine in humans (Bullingham et al., 1998; Gao et al., 2011). The contributions of canalicular efflux of intracellularly formed MPAG to net (basolateral and canalicular) efflux were estimated to be 37% in rat SCHs and 20% in human SCHs, suggesting species differences in the direction of basolateral and canalicular efflux of MPAG (Tetsuka et al., 2014b).

These independent reports using SCH systems suggest that species differences in urinary and fecal/biliary excretion of M1-glucuronide and MPAG depend on biliary excretion availability because these metabolites are substrates of MRP2/Mrp2. For troglitazone, in contrast, there are no significant species differences in the metabolism of the parent drug and the urinary/biliary excretion balance of the main metabolite (troglitazone sulfate) between rat and human SCHs, and these is also

TABLE 1
Activities of uptake transporters in SCHs and hepatocytes in suspension

Substrate	Accumulation (pmol/min/mg protein or 10^6 cells) or Uptake Clearance ($\mu\text{L}/\text{min}/\text{mg}$ protein)		References
	SCHs	Suspended Hepatocytes	
CCK-8 (human)	1.06 $\mu\text{L}/\text{min}/\text{mg}$ protein	2.44 $\mu\text{L}/\text{min}/\text{mg}$ protein	Kotani et al. (2011)
Digoxin (human)	3.8 $\pm$ 1.7 pmol/min per 10^6 cells	5.2 $\pm$ 2.6 pmol/min per 10^6 cells	De Bruyn et al. (2011)
Estrone-3-sulfate (human)	30.3 $\pm$ 13.0 pmol/min per 10^6 cells	99.1 $\pm$ 67 pmol/min per 10^6 cells	De Bruyn et al. (2011)
1-Methyl-4-phenylpyridinium (MPP+) (rat)	~17 pmol/min/mg protein	91 pmol/min/mg protein	Jacobsen et al. (2011)
Pravastatin (human)	2.95 $\mu\text{L}/\text{min}/\text{mg}$ protein	2.17 $\mu\text{L}/\text{min}/\text{mg}$ protein	Kotani et al. (2011)
Rosuvastatin (human)	9.48 $\mu\text{L}/\text{min}/\text{mg}$ protein	9.50 $\mu\text{L}/\text{min}/\text{mg}$ protein	Kotani et al. (2011)
TCA (human)	20.0 $\pm$ 7.9 pmol/min per 10^6 cells	27.5 $\pm$ 15 pmol/min per 10^6 cells	De Bruyn et al. (2011)
TCA (rat)	40.8 $\pm$ 5.7 pmol/min/mg protein at 10 μM	52.8 $\pm$ 10.2 pmol/min/mg protein at 1 μM	Kemp et al. (2005)

TABLE 2
Hepatic transporters involved in parent drug and metabolite pairs

Drugs and Metabolites	Basolateral Uptake Transporters	Basolateral Efflux Transporters	Canalicular Efflux Transporters	References
Bilirubin	OATP1B1, OATP1B3	NA	NA	Lengyel et al. (2005);
Bilirubin mono/diglucuronide	OATP1B1	Mrp1, MRP3	BCRP, MRP2/Mrp2	van de Steeg et al. (2012); Chang et al. (2013)
Diclofenac	Not substrate of either OATP1B1, OATP1B3, or OATP2B1	Not substrate of MRP3	Not substrate of either BCRP or MRP2	Zhang et al. (2016)
Diclofenac acyl glucuronide	OATP1B1, OATP2B1	MRP3	BCRP, MRP2	
Enalapril	OATP1B1, OATP1B3	Not substrate of either MRP3 or MRP4	MRP2/Mrp2	Liu et al. (2006); Ferslew et al. (2014)
Enalaprilat	NA	MRP4	MRP2/Mrp2	
Ezetimibe	Not substrate of either OATP1B1, OATP1B3 or OATP2B1	NA	Not substrate of MRP2	Oswald et al. (2008); Fahrmayr et al. (2012)
Ezetimibe glucuronide	OATP1B1, OATP2B1	NA	MRP2	
Irinotecan	Not substrate of OATP1B1	NA	P-gp, MRP2	Nozawa et al. (2005);
SN-38	OATP1B1	NA	BCRP, P-gp, MRP2	Di Martino et al. (2011)
SN-38 glucuronide	Not substrate of OATP1B1	NA	MRP2	
Morphine	OCT1	Not substrate of MRP3	P-gp	Tzvetkov et al. (2013);
Morphine 6-glucuronide	NA	MRP3	P-gp, MRP2	Venkatasubramanian et al. (2014)
Paroxetine	NA	NA	NA	Matsunaga et al. (2013)
M1-glucuronide	NA	NA	MRP2/Mrp2	
M1-sulfate	NA	NA	Not substrate of either MRP2/Mrp2, BCRP/Bcrp, or BSEP/Bsep	
Mycophenolate mofetil	NA	NA	NA	Picard et al. (2010);
Mycophenolic acid (MPA)	Not substrate of OATPs	NA	NA	Matsunaga et al. (2014);
MPA phenyl-glucuronide (MPAG)	OATP1B1, OATP1B3	MRP3, MRP4	MRP2/Mrp2	Tetsuka et al. (2014b)
Troglitazone	NA	NA	NA	Enokizono et al. (2007);
Troglitazone sulfate	OATP1B1	Mrp3, Mrp4	BCRP, MRP2	Lee et al. (2010)

NA, not applicable; SN-38, 7-ethyl-10-hydroxycamptothecin.

in good agreement with the *in vivo* disposition of troglitazone sulfate in both species (Lee et al., 2010). These findings show that SCHs can reproduce the *in vivo* hepatic disposition of a parent drug and metabolite and predict species differences.

OATP1B1 and OATP1B3 are involved in bilirubin and its glucuronide uptake to the liver. In addition, UGT1A1 catalyzes bilirubin conjugation to monoglucuronide (BMG) and diglucuronide (BDG), and subsequent biliary excretion is mediated by MRP2. Drug-induced hyperbilirubinemia is thought to be caused by inhibition of either UGT1A1 or these transporters (Chang et al., 2013; Keppler, 2014). The sum of BEIs of the formed bilirubin glucuronides (BMG and BDG) was 80.6% in rat SCHs and 62.5% in human SCHs, suggesting that bilirubin glucuronides are preferably excreted into the canalicular networks in both rats and humans. In rat SCHs, formations of BMG and BDG were comparable, whereas the excreted amount of BDG into bile canaliculi was higher than that of BMG in rat SCHs (Lengyel et al., 2005). The kinetic parameters of rat Mrp2 were $0.8 \pm 0.2 \mu\text{mol/l}$ of K_m and $213 \pm 52 \mu\text{l/min}$ per milligram protein of CL_{int} for BMG and $0.5 \pm 0.1 \mu\text{mol/l}$ of K_m and $520 \pm 24 \mu\text{l/min}$ per milligram protein of CL_{int} for BDG, respectively (Kamisako et al., 1999), suggesting that BDG is a better-transported substrate of rat Mrp2, which is consistent with *in vivo* observations. In addition, the BDG/BMG ratio in the medium (0.55) and bile canaliculi (1.48) in rat SCHs was comparable to those in serum (0.6) and bile (1.5) of rats (Mesa et al., 1997; Lengyel et al., 2005). These findings suggest that SCHs enable evaluation of basolateral and canalicular membrane transport of bilirubin glucuronides.

The BDG/BMG ratio in bile and serum changes in different types of hyperbilirubinemia. For instance, in Gilbert and Crigler-Najjar syndromes, which are caused by genetic polymorphisms of UGT1A1 and exhibit decreased or deficient glucuronidation activities, there is a shift toward BMG, consistent with a decrease of the BDG/BMG ratio in bile and serum in Gunn rats, an animal model of Crigler-Najjar syndrome (Van Steenberg and Fevery, 1990; Clarke et al., 1997). In contrast,

bile duct-ligated and Mrp2-deficient rats, a model of Dubin-Johnson syndrome, have an increased BDG/BMG ratio in bile and serum, corresponding to clinical findings in patients with extrahepatic cholestasis (Jansen et al., 1985; Sieg et al., 1986; Mesa et al., 1997). These results show that the mechanism of drug-induced hyperbilirubinemia could be explored by measuring the BDG/BMG ratio in SCHs. To establish the usefulness of the BMG/BDG ratio change in SCHs for investigating drug-induced hyperbilirubinemia, further studies are essential using a number of drugs that cause hyperbilirubinemia.

Probe Selection to Evaluate Drug-Drug Interactions via Canalicular Efflux Transporters

SCHs can form a bile canalicular network, and this allows investigation of intact cell-based interactions with canalicular transporters. Among the canalicular transporters expressed in hepatocytes, BCRP, BSEP, P-gp, and MRP2 are important efflux transporters that are involved in drug-drug interactions (DDIs). MRP2 substrates are mostly conjugated metabolites, including MPAG and BMG/BDG, and MRP2 inhibition indirectly leads to a DDI via the decrease of enterohepatic circulation of metabolites such as MPAG or results in conjugated hyperbilirubinemia. In addition, inhibition of BSEP is considered to cause liver injury (Hillgren et al., 2013).

Several fluorescent or radiolabeled probes have been used to determine the interaction with canalicular efflux transporters in SCHs, but these probes are often substrates of both basolateral uptake and canalicular efflux transporters. For instance, estrone 3-sulfate, taurocholate (TCA), rhodamine 123, and estradiol 17 β -D-glucuronide (E17G) are generally used as model substrates for BCRP, BSEP, P-gp, and MRP2, respectively; however, they are also substrates of OATPs and/or NTCP (Annaert and Brouwer, 2005; McRae et al., 2006; Fukuda et al., 2008; Brouwer et al., 2013; Pedersen et al., 2013). In addition, some probes, such as E17G and TCA, are substrates of basolateral efflux transporter

MRP3 and/or MRP4 (Hirohashi et al., 1999; Hirohashi et al., 2000; Akita et al., 2002; Rius et al., 2006).

BEI is frequently used as a marker for inhibition of canalicular transport in SCHs and is determined from intracellular and bile canaliculi-excreted accumulations of substrate, based on eq. 2. Because intracellular substrate accumulation is affected by basolateral uptake and efflux as well as by metabolism, the assessment of canalicular transporter-mediated interactions based on BEI is complicated. Caution should be taken as to whether the perpetrator exhibits inhibitory potential for multiple transporters and/or drug metabolizing enzymes in hepatocytes.

The fluorescent probe 5(6)-carboxy-2',7'-dichlorofluorescein (CDF) is a substrate of MRP2 and is used as a marker of MRP2 function; however, CDF is also a substrate of basolateral uptake and efflux transporters OATPs and MRP3 (Zamek-Gliszczynski et al., 2003; Ellis et al., 2014). In contrast, 5(6)-carboxy-2',7'-dichlorofluorescein diacetate (CDFDA) is a nonfluorescent ester form of CDF with uptake into hepatocytes that is not saturable, temperature dependent, or impaired by transporter inhibitors (Zamek-Gliszczynski et al., 2003), suggesting that CDFDA crosses the membrane mainly by passive diffusion. Once CDFDA is in the cells, it is rapidly hydrolyzed by intracellular esterases to the fluorescent probe CDF, which is subsequently actively transported out to bile canaliculi by MRP2 in SCHs.

This enzyme–efflux transporter interplay of CDFDA/CDF has been applied in the SCH system as a quantitative time-lapse imaging (QTLI) method to investigate MRP2-mediated interaction by time-dependent detection of fluorescent dye in bile canaliculi of SCHs, regardless of whether the perpetrator has an inhibitory potential for basolateral uptake transporters (Nakanishi et al., 2011, 2012).

Most of the MRP2 substrates are not parent drugs but conjugated metabolites, and the inhibition causes the decrease of the enterohepatic circulation, leading to an indirect DDI. MRP2 inhibition also results in conjugated hyperbilirubinemia. Therefore, investigation of MRP2 inhibition is considered clinically relevant. In addition, as well as other transporters such as OATPs (Noé et al., 2007; Tamai and Nakanishi, 2013; Hoshino et al., 2016), MRP2 is considered to have multiple binding sites (Gilibili et al., 2017). A typical MRP2 substrate E17G follows the sigmoidal kinetics in MRP2-mediated uptake to membrane vesicles with high and low affinities, whereas the uptake of CDF and an endogenous substrate coproporphyrin-I (CP-I) exhibits the simple Michaelis-Menten kinetics, suggesting CDF and CP-I are the more preferred substrates for investigation of MRP2 inhibition. Although CP-I is endogenous and may be used as a biomarker of MRP2 function in vivo, it is also a substrate of OATPs (Shen et al., 2016). Accordingly, QTLI using CDFDA allows direct measurement of fluorescent dye

accumulation in bile canaliculi over time without calcium/magnesium depletion, giving a time- and cost-effective in vitro system for screening for MRP2 inhibition at an early stage of drug development.

QTLI also enables prediction of apparent inhibition of MRP2 by metabolites formed in the hepatocytes, even when the metabolites are not identified. A similar QTLI method has been used to investigate BSEP function using a fluorescent bile acid (BA) derivative *N*-(24-[7-(4-*N,N*-dimethylaminosulfonyl-2,1,3-benzoxadiazole)]amino-3 α ,7 α ,12 α -trihydroxy-27-nor-5 β -cholestan-26-oyl)-2'-aminoethanesulfonate (tauro-nor-THCA-24-DBD). However, the uptake of tauro-nor-THCA-24-DBD is mediated by NTCP and OATPs and affected by their inhibitors (De Bruyn et al., 2014). Rhodamine 123 is a fluorescent substrate used for assessment of P-gp function that can be applied for QTLI analysis; however, it is also an Oatp substrate in rats (Annaert and Brouwer, 2005). In many cases, interactions with basolateral uptake transporters must be taken into account in hepatobiliary transport in SCHs because the probe is often a substrate of both basolateral uptake and canalicular efflux transporters. Therefore, enzyme–efflux transporter interplay in SCHs may allow separation of involvement of basolateral uptake transporters from hepatobiliary transport using more selective probes such as CDFDA/CDF.

More Clinically Relevant Prediction of DDIs by Enzyme–Transporter Interplay

Enzyme–efflux transporter interplay in SCHs is sometimes useful for prediction of more clinically relevant DDIs. Candesartan cilexetil (CCX) is rapidly hydrolyzed to the active form candesartan (CAN) by esterases in the liver. CCX is a more potent inhibitor of human BSEP than CAN in vesicular transport assays using membrane vesicles prepared from BSEP-expressing cells (IC_{50} values of CCX and CAN for human BSEP are 6.2 and 70.5 μ M, respectively), whereas exposing CCX to human SCHs did not affect the hepatobiliary transport of TCA (66.5% in control versus 62.7% in CCX as BEI) (Fukuda et al., 2014). Diisopropyl fluorophosphate, an irreversible cholinesterase inhibitor, significantly inhibited the metabolism of CCX to CAN in human SCHs and resulted in a significant decrease of BEI for TCA due to an increase of intracellular CCX concentration and subsequent inhibition of human BSEP activity (Fukuda et al., 2014). These findings are consistent with the low risk of CCX for liver dysfunction or jaundice in clinical use (Fig. 3A).

Another example is a situation in which the metabolite causes a DDI, rather than the parent. Estradiol (E_2) itself is not a substrate of MRP2, but its metabolite E17G is a substrate. E_2 does not affect rat MRP2-mediated uptake of CDF up to 300 μ M in vesicular transport experiments,

Fig. 3. SCHs allows clinically and in vivo relevant prediction of DDIs caused by both parent drug and metabolite hepatic exposure. (A) Candesartan cilexetil (CCX) is a potent human BSEP inhibitor, but it is rapidly hydrolyzed in hepatocytes to candesartan (CAN), which is a weak inhibitor of BSEP, consistent with the low risks of cholestatic jaundice in clinical use of CCX (Fukuda et al., 2014). (B) Estradiol (E_2) has no potency for rat MRP2, but its metabolite, estradiol 17 β -D-glucuronide (E17G), is a potent MRP2 inhibitor, leading to acute cholestasis in rats (Meyers et al., 1980, 1981; Nakanishi et al., 2012).

TABLE 3

Established mathematical models of parent and metabolites obtained from SCH-based data

Drugs and Metabolites	Remarks	References
Terfenadine	~15% as BEI, $k_{\text{efflux}} \gg k_{\text{bile}}$ in rat SCHs	Turncliff et al. (2006)
Fexofenadine	~15% as BEI, $k_{\text{efflux}} > k_{\text{bile}}$ in rat SCHs	
Troglitazone	Minimum biliary excretion in rat SCHs	Lee et al. (2010)
Troglitazone glucuronide	~50% as BEI, $k_{\text{efflux}} > k_{\text{bile}}$ in rat SCHs	
Troglitazone sulfate	~20% as BEI, $k_{\text{efflux}} < k_{\text{bile}}$ in rat SCHs	
Pafuramidine	Rapidly metabolized in rat and human SCHs	Yan et al. (2011, 2012)
Furamidine (active form of pafuramidine)	$k_{\text{efflux}} > k_{\text{bile}}$ in rat and human SCHs	
CPD-0868	Rapidly metabolized in rat SCHs	Yan et al. (2011)
CPD-0801 (active form of CPD-0868)	$k_{\text{efflux}} > k_{\text{bile}}$ in rat SCHs	
Mycophenolic acid (MPA)	Rapidly metabolized in human SCHs	Matsunaga et al. (2014)
MPA phenyl-glucuronide (MPAG)	~40% as BEI, $k_{\text{efflux}} > k_{\text{bile}}$ in human SCHs	
Bosentan	Minimum biliary excretion in human SCHs	Matsunaga et al. (2016)
Ro 48-5033	$k_{\text{efflux}} = k_{\text{bile}}$ in human SCHs	
Ro 47-8634	$k_{\text{efflux}} = k_{\text{bile}}$ in human SCHs	
Ro 64-1056	$k_{\text{efflux}} = k_{\text{bile}}$ in human SCHs	

BEI, biliary excretion index; CPD-0801, 2,5-bis (5-amidino)-2-pyridyl furan; CPD-0868, 2,5-bis [5-(*N*-methoxyamidino)-2-pyridyl] furan; k_{bile} , biliary excretion rate from cells to bile canaliculi; k_{efflux} , efflux rate from cells to buffer; OCT1, organic cation transporter 1.

whereas E17G showed preloading time- and concentration-dependent inhibition of Mrp2 function in rat SCHs using QTLI with CDFDA/CDF (Nakanishi et al., 2012). Because the preloading time- and concentration-dependent formation of E17G was observed after adding E₂ to rat SCHs, and E17G directly inhibited CDF uptake in Mrp2-expressing vesicles in a concentration-dependent manner (Nakanishi et al., 2012), the effect of E₂ on Mrp2 function in rat SCHs is apparently indirect, via formation of E17G (Fig. 3B). This corresponds to in vivo acute cholestasis in rats after administration of E₂ (Meyers et al., 1980, 1981). Therefore, SCHs can provide clinically and in vivo relevant DDI predictions based on hepatic exposures of both a parent drug and intracellularly formed metabolites.

Utility of Mechanistic Modeling of Hepatic Disposition of Parent Drugs and Metabolites

The utility of modeling and simulation in drug development has been widely recognized and illustrated (Huang et al., 2013; Milligan et al., 2013). Some multicompartiment models are useful for understanding the dynamic disposition of the parent drug and metabolites mechanistically in hepatocytes. Cryopreserved hepatocytes are more convenient and flexible to study drug transport compared with freshly isolated hepatocytes. There is debate about changes of uptake transporter activities in hepatocytes during cryopreservation, with similar or fewer uptake activities in suspended hepatocytes after thawing (Houle et al., 2003; Badolo et al., 2011; Brouwer et al., 2013; Lundquist et al., 2014). In addition, There is some debate on efflux transporter function in suspended or monolayer hepatocytes, but in general these transporters are assumed to be internalized after isolation or short-term culturing and their activities can be negligible, especially in short-term incubation (Hewitt et al., 2007; Jørgensen et al., 2007; Bow et al., 2008).

In contrast, SCHs are expected to retain an entire array of transporter and drug metabolizing-enzyme activities in the liver, and all four processes of hepatic disposition can be simultaneously determined in SCHs. Accordingly, modeling SCH-based data enables simultaneous estimation of in vitro transporter- and enzyme-mediated parameters, in addition to passive diffusion and intracellular binding.

Three compartments (buffer, cell, and bile canaliculi) are generally used for mathematical modeling in SCHs, shown in Supplemental Figure 1. Rich input data obtained by monitoring parent drug and metabolites over time are necessary to estimate the parameters precisely. A flux from bile canaliculi to buffer is technically present in SCHs, and

this has to be taken into account in the model (Matsunaga et al., 2014). For estimating basolateral efflux, at least two methods (one- or two-step) have been proposed (Turncliff et al., 2006; Lee et al., 2010; Pfeifer et al., 2013a; Matsunaga et al., 2014, 2016; Guo et al., 2016). Establishing an in vitro mechanistic model leads to further analyses, such as sensitivity analysis, DDI prediction, and identification of a novel metabolic pathway (Lee et al., 2010; Matsunaga et al., 2014, 2015, 2016; Guo et al., 2016). In vitro parameter estimates from SCH-based data can also be extrapolated to the whole liver level and subsequently incorporated into physiologically based pharmacokinetics models (Yan et al., 2011; Yan et al., 2012; Pfeifer et al., 2013b). Mathematical models of pairs of parent drug and metabolite in SCHs are summarized in Table 3.

Fig. 4. Hepatic disposition of MPA and MPAG and DDI with CsA. MPA is predominantly metabolized to MPAG in human liver. The formed MPAG is transported to the bloodstream by basolateral efflux transporters MRP3 and MRP4 and to the bile by the canalicular efflux transporter MRP2 (Matsunaga et al., 2014). Concomitant drug CsA inhibits OATP-mediated uptake and MRP2-mediated canalicular efflux of MPAG at clinically relevant concentrations, and subsequent systemic exposure of MPAG is increased (Naito et al., 2009; Yau et al., 2009).

Modeling of Hepatic Disposition of MPA and MPAG and Interactions with Cyclosporine A in Human SCHs

MPA is widely used as an immunosuppressive agent, especially after renal transplantation, and is predominantly metabolized to MPAG (Shipkova et al., 2001). MPAG is considered to undergo biliary excretion and to contribute to the continuous systemic exposure of MPA via the enterohepatic circulation. However, the systemic exposure of MPAG is much greater than that of MPA and the administered MPA is eventually excreted in urine at ~90% of the dose as MPAG (Bullingham et al., 1998). In human SCHs, MPA was primarily converted to MPAG, and the formed MPAG was a preferred substrate of MRP2 with ~50% BEI. In contrast, mechanistic modeling of MPA and MPAG disposition in human SCHs revealed that the basolateral efflux rate of formed MPAG was 2.4 times faster than the canalicular efflux rate, corresponding to the *in vivo* observation that MPAG is excreted into bile but the systemic exposure is high. MPAG is a substrate of basolateral efflux transporters MRP3 and MRP4, and the sensitivity analysis of the model suggested a significant impact of functional change of basolateral efflux activities on MPAG disposition (Matsunaga et al., 2014).

MPA is usually used in combination with a calcineurin inhibitor, such as cyclosporin A (CsA) or tacrolimus, in immunosuppressive therapy (Staatz and Tett, 2007). CsA is a well-known inhibitor of several drug metabolizing-enzymes and transporters in clinical use (Zhang et al., 2008; Liu et al., 2011). Indeed, concurrent administration of CsA causes decreased exposure of MPA in patients by inhibition of MRP2-mediated biliary excretion and subsequent reduction of enterohepatic circulation of MPAG (Smak Gregoor et al., 1999; Hesselink et al., 2005; Tetsuka et al., 2014b). In human SCHs, CsA decreased the BEI of MPAG and increased intracellular MPAG accumulation in a concentration-dependent manner, whereas CsA did not affect MPA disposition or formation of MPAG (Matsunaga et al., 2015).

The established *in vitro* hepatic disposition model of MPA and MPAG in human SCHs was applied to investigate the effects of CsA on MPAG disposition, and revealed that CsA had different inhibitory potencies for basolateral and canalicular efflux transporter-mediated MPAG disposition of ~50% and ~80%, respectively, as maximum inhibition. In addition, model-based analysis suggested that at clinically relevant concentrations of CsA, the extracellular medium concentration of MPAG was increased by inhibition of OATP-mediated uptake and

Fig. 5. Hepatic disposition of bosentan and its metabolites in human liver. Bosentan is metabolized by CYP2C9 and CYP3A to Ro 48-5033 and Ro 47-8634. Ro 47-8634 is further metabolized to Ro 64-1056 and M4, a novel metabolite found by a modeling approach (Matsunaga et al., 2016). Ro 64-1056 exhibits concentration-dependent cytotoxicity in human hepatocytes, and the metabolic pathway from Ro 47-8634 to M4 is considered to be an alternative route that avoids Ro 64-1056-induced hepatotoxicity.

MRP2-mediated biliary excretion of MPAG (Matsunaga et al., 2015) (Fig. 4). This result is consistent with clinical observations (Naito et al., 2009; Yau et al., 2009). Thus, the MPA and MPAG pair is a good example with which to understand the utility of mathematical modeling of SCH-based data.

Identification of Novel Metabolic Pathways and Improved Understanding of Hepatotoxicity

A quantitative mechanistic analysis can provide previously unknown information. Bosentan, an oral nonselective endothelin receptor antagonist, is metabolized in human liver to Ro 48-5033 (hydroxylated form [4-(2-hydroxy-1,1-dimethyl-ethyl)-N-[6-(2-hydroxy-ethoxy)-5-(2-methoxyphenoxy)-[2,2#1;]bipyrimidinyl-4-yl]-benzenesulfonamide]) or Ro 47-8634 (O-demethylated form [4-tert-butyl-N-[6-(2-hydroxyethoxy)-5-(2-hydroxyphenoxy)-2-(pyrimidin-2-yl)pyrimidin-4-yl]benzene-1-sulfonamide]) and is subsequently metabolized to Ro 64-1056 (combination of hydroxylation and O-demethylation [4-(1-hydroxy-2-methylpropan-2-yl)-N-[5-(2-hydroxyphenoxy)-2-pyrimidin-2-yl-6-(1,1,2,2-tetradeuterio-2-hydroxyethoxy)pyrimidin-4-yl]benzenesulfonamide]) (Matsunaga et al., 2016).

Bosentan is a hepatotoxic drug, but its mechanism is not fully understood. In human SCHs, the total recovered amounts of bosentan and its three metabolites after incubation was 88.3%–111.9% of the dose added, but a mathematical model of known metabolic pathways failed to predict the disposition of the drug and metabolites in human SCHs. An unknown metabolite peak was found in bioanalyses of SCH samples, which was determined to be a hydroxylated form of Ro 47-8634 and named M4 (Matsunaga et al., 2016). A modified model including the new M4 pathway successfully predicted the disposition of bosentan and its metabolites in human SCHs. The pathway from Ro 47-8634 to M4 is an alternative route avoiding Ro 64-1056–induced hepatotoxicity because Ro 64-1056 decreased cell viability in a concentration-dependent manner and the cytotoxicity was ameliorated by inhibition of metabolism of Ro 47-8634 to Ro 64-1056 (Fig. 5).

Drug-induced liver injury is triggered by various mechanisms, including reactive metabolite formation and mitochondrial dysfunction, and BSEP inhibition is a risk factor for hepatotoxicity due to cholestasis. As SCHs can form a canalicular network, SCH-based models have been proposed to examine drug-induced cholestasis in combination with a BA mixture (Ogimura et al., 2011; Chatterjee et al., 2014a; Oorts et al., 2016). In some cases, metabolites show similar or more potent inhibition of BSEP function, e.g., Ro 47-8634 (bosentan) and DM-4103 (tolvaptan) (Fattinger et al., 2001; Slizgi et al., 2016); therefore, in vitro modeling of the parent drug and metabolite in SCHs is informative for understanding the mechanism of the cholestatic effect by metabolic activation.

It is also of note that BA composition differs between rats and humans and each BA exhibits different properties of hydrophobicity, toxicity, and interplay with multiple transporters and enzymes (Alvaro et al., 1986; Tagliacozzi et al., 2003; Chatterjee et al., 2014b; Rodrigues et al., 2014). In addition, unconjugated BA is conjugated with glycine or taurine in SCHs during incubation (Marion et al., 2011), and bile acid CoA:amino acid N-acyltransferase catalyzes this reaction. As some genetic polymorphisms altering catalytic properties are found in coding regions of the enzyme (Tougou et al., 2007), a functional change of this enzyme may also influence BA-related hepatotoxicity. Accordingly, in addition to the analysis of disposition of a perpetrating drug and its metabolite, mathematical modeling of BA composition in SCHs should be useful to understand BA-triggered hepatotoxicity mechanistically.

Conclusion

To date, transporters and drug-metabolizing enzymes have been identified and characterized extensively. The next stage in this area is to predict functional interplay between transporters and drug-metabolizing enzymes to determine the $CL_{int,H}$ of NCEs based on the extended clearance concept (Varma and El-Kattan, 2016). In addition, basolateral and canalicular efflux transporters determine the fate of metabolites formed in the liver, and enzyme–efflux transporter interplay has also been considered for metabolites.

As SCHs maintain metabolic activities and can form a canalicular network, they can be used to investigate the interplay between uptake/efflux transporters and drug-metabolizing enzymes. Indeed, SCHs allow mimicry of species-specific disposition of a parent drug and metabolites in vivo. SCHs are also useful for clinically relevant prediction of DDIs caused by a parent drug and/or metabolite. In addition, mathematical modeling of hepatic disposition of drugs and metabolites in SCHs provides considerable information for mechanistic and quantitative understanding of the event and incorporation into physiologically based pharmacokinetics model simulations.

Tissue engineering is a growing research field, and a number of technologies and newly advanced culture systems, such as cocultures with fibroblasts, have been provided to better reflect in vivo situations (Tetsuka et al., 2017). For instance, HepatoPac, one of the most famous coculture models, has demonstrated longer-term stable expression of drug-metabolizing enzymes as well as basolateral uptake and canalicular efflux transporters (Ramsden et al., 2014; Li et al., 2017). This and other newly developed culture systems may overcome the disadvantage of SCHs; however, a great advantage still exists with SCHs as they have a longer research history for bile canaliculi formation and excretion. Further work will be expected to expand the utility and applicability of hepatocyte-based data including SCHs and other advanced models.

Authorship Contributions

Participated in research design: Matsunaga, Fukuchi, Imawaka, Tamai.

Wrote or contributed to the writing of the manuscript: Matsunaga, Fukuchi, Imawaka, Tamai.

References

- Akita H, Suzuki H, Hirohashi T, Takikawa H, and Sugiyama Y (2002) Transport activity of human MRP3 expressed in Sf9 cells: comparative studies with rat MRP3. *Pharm Res* **19**:34–41.
- Alvaro D, Cantafora A, Attili AF, Ginanni Corradini S, De Luca C, Minervini G, Di Biase A, and Angelico M (1986) Relationships between bile salts hydrophilicity and phospholipid composition in bile of various animal species. *Comp Biochem Physiol B* **83**:551–554.
- Aniceto N, Freitas AA, Bender A, and Ghafourian T (2016) Simultaneous prediction of four ATP-binding cassette transporters' substrates using multi-label QSAR. *Mol Inform* **35**:514–528.
- Annaert PP and Brouwer KL (2005) Assessment of drug interactions in hepatobiliary transport using rhodamine 123 in sandwich-cultured rat hepatocytes. *Drug Metab Dispos* **33**:388–394.
- Argikar UA, Potter PM, Hutzler JM, and Marathe PH (2016) Challenges and opportunities with non-CYP enzymes aldehyde oxidase, carboxylesterase, and UDP-glucuronosyltransferase: focus on reaction phenotyping and prediction of human clearance. *AAPS J* **18**:1391–1405.
- Badée J, Achour B, Rostami-Hodjegan A, and Galetin A (2015) Meta-analysis of expression of hepatic organic anion-transporting polypeptide (OATP) transporters in cellular systems relative to human liver tissue. *Drug Metab Dispos* **43**:424–432.
- Badolo L, Trancart MM, Gustavsson L, and Chesné C (2011) Effect of cryopreservation on the activity of OATP1B1/3 and OCT1 in isolated human hepatocytes. *Chem Biol Interact* **190**:165–170.
- Bi YA, Kazolias D, and Duignan DB (2006) Use of cryopreserved human hepatocytes in sandwich culture to measure hepatobiliary transport. *Drug Metab Dispos* **34**:1658–1665.
- Blaheta RA, Kronenberger B, Woitaschek D, Auth MK, Scholz M, Weber S, Schuldes H, Encke A, and Markus BH (1998) Dedifferentiation of human hepatocytes by extracellular matrix proteins in vitro: quantitative and qualitative investigation of cytokeratin 7, 8, 18, 19 and vimentin filaments. *J Hepatol* **28**:677–690.
- Bow DA, Perry JL, Miller DS, Pritchard JB, and Brouwer KL (2008) Localization of P-gp (Abcb1) and MRP2 (Abcc2) in freshly isolated rat hepatocytes. *Drug Metab Dispos* **36**:198–202.
- Brouwer KL, Keppler D, Hoffmaster KA, Bow DA, Cheng Y, Lai Y, Palm JE, Stieger B, and Evers R; International Transporter Consortium (2013) In vitro methods to support transporter evaluation in drug discovery and development. *Clin Pharmacol Ther* **94**:95–112.
- Bullingham RE, Nicholls AJ, and Kamm BR (1998) Clinical pharmacokinetics of mycophenolate mofetil. *Clin Pharmacokinet* **34**:429–455.
- Center for Drug Evaluation and Research (CDER) (2016) *Safety Testing for Drug Metabolites: Guidance for Industry*. Revision 1. U.S. Department of Health and Human Services, Food and

- Drug Administration, Rockville, MD. <https://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM079266>.
- Center for Drug Evaluation and Research (CDER) and Center for Drug Evaluation and Research (CDER) (2010) *Guidance for Industry: M3(R2) Nonclinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals*. Revision 1. U.S. Department of Health and Human Services, Food and Drug Administration, Rockville, MD. <https://www.fda.gov/downloads/drugs/guidances/ucm073246.pdf>.
- Chang JH, Plise E, Cheong J, Ho Q, and Lin M (2013) Evaluating the in vitro inhibition of UGT1A1, OATP1B1, OATP1B3, MRP2, and BSEP in predicting drug-induced hyperbilirubinemia. *Mol Pharm* **10**:3067–3075.
- Chatterjee S, Bijsmans IT, van Mil SW, Augustijns P, and Annaert P (2014b) Toxicity and intracellular accumulation of bile acids in sandwich-cultured rat hepatocytes: role of glycine conjugates. *Toxicol In Vitro* **28**:218–230.
- Chatterjee S, Richert L, Augustijns P, and Annaert P (2014a) Hepatocyte-based in vitro model for assessment of drug-induced cholestasis. *Toxicol Appl Pharmacol* **274**:124–136.
- Chiba M, Ishii Y, and Sugiyama Y (2009) Prediction of hepatic clearance in human from in vitro data for successful drug development. *AAPS J* **11**:262–276.
- Choi MK, Kim H, Han YH, Song IS, and Shim CK (2009) Involvement of Mrp2/MRP2 in the species different excretion route of benzylpenicillin between rat and human. *Xenobiotica* **39**:171–181.
- Clarke DJ, Moghrabi N, Monaghan G, Cassidy A, Boxer M, Hume R, and Burchell B (1997) Genetic defects of the UDP-glucuronosyltransferase-1 (UGT1) gene that cause familial non-haemolytic unconjugated hyperbilirubinaemia. *Clin Chim Acta* **266**:63–74.
- De Bruyn T, Sempels W, Snoeys J, Holmstock N, Chatterjee S, Stieger B, Augustijns P, Hofkens J, Mizuno H, and Annaert P (2014) Confocal imaging with a fluorescent bile acid analogue closely mimicking hepatic taurocholate disposition. *J Pharm Sci* **103**:1872–1881.
- De Bruyn T, Ye ZW, Peeters A, Sahi J, Baes M, Augustijns PF, and Annaert PP (2011) Determination of OATP-, NTPC- and OCT-mediated substrate uptake activities in individual and pooled batches of cryopreserved human hepatocytes. *Eur J Pharm Sci* **43**:297–307.
- de Lannoy IA and Pang KS (1987) Effect of diffusional barriers on drug and metabolite kinetics. *Drug Metab Dispos* **15**:51–58.
- Di L, Keefer C, Scott DO, Strelevitz TJ, Chang G, Bi YA, Lai Y, Duckworth J, Fenner K, Troutman MD, et al. (2012) Mechanistic insights from comparing intrinsic clearance values between human liver microsomes and hepatocytes to guide drug design. *Eur J Med Chem* **57**:441–448.
- Di L and Obach RS (2015) Addressing the challenges of low clearance in drug research. *AAPS J* **17**:352–357.
- Di Martino MT, Arbitrio M, Leone E, Guzzi PH, Rotundo MS, Ciliberto D, Tomaino V, Fabiani F, Talardo D, Sperlongano P, et al. (2011) Single nucleotide polymorphisms of ABCG2 and ABCG1 transporter genes correlate to irinotecan-associated gastrointestinal toxicity in colorectal cancer patients: a DMET microarray profiling study. *Cancer Biol Ther* **12**:780–787.
- Dunn JC, Yarmush ML, Koebe HG, and Tompkins RG (1989) Hepatocyte function and extracellular matrix geometry: long-term culture in a sandwich configuration. *FASEB J* **3**:174–177.
- Ellis LC, Grant MH, Hawksworth GM, and Weaver RJ (2014) Quantification of biliary excretion and sinusoidal excretion of 5(6)-carboxy-2',7'-dichlorofluorescein (CDF) in cultured hepatocytes isolated from Sprague Dawley, Wistar and Mrp2-deficient Wistar (TR^{-/-}) rats. *Toxicol In Vitro* **28**:1165–1175.
- Enokizono J, Kusuhaara H, and Sugiyama Y (2007) Involvement of breast cancer resistance protein (BCRP/ABCG2) in the biliary excretion and intestinal efflux of troglitazone sulfate, the major metabolite of troglitazone with a cholestatic effect. *Drug Metab Dispos* **35**:209–214.
- Fahrmayr C, König J, Auge D, Mieth M, and Fromm MF (2012) Identification of drugs and drug metabolites as substrates of multidrug resistance protein 2 (MRP2) using triple-transfected MDCK-OATP1B1-UGT1A1-MRP2 cells. *Br J Pharmacol* **165**:1836–1847.
- Fattinger K, Funk C, Pantze M, Weber C, Reichen J, Stieger B, and Meier PJ (2001) The endo-thelin antagonist bosentan inhibits the canalicular bile salt export pump: a potential mechanism for hepatic adverse reactions. *Clin Pharmacol Ther* **69**:223–231.
- Food and Drug Administration (2016) Guidance for industry: Safety Testing of Drug Metabolites. Center for Drug Evaluation and Research (CDER) <https://www.fda.gov/downloads/Drugs/.../Guidances/ucm079266.pdf>
- Ferslew BC, Köck K, Bridges AS, and Brouwer KL (2014) Role of multidrug resistance-associated protein 4 in the basolateral efflux of hepatically derived enalaprilat. *Drug Metab Dispos* **42**:1567–1574.
- Frank R and Hargreaves R (2003) Clinical biomarkers in drug discovery and development. *Nat Rev Drug Discov* **2**:566–580.
- Fukuda H, Nakanishi T, and Tamai I (2014) More relevant prediction for in vivo drug interaction of candesartan cilexetil on hepatic bile acid transporter BSEP using sandwich-cultured hepatocytes. *Drug Metab Pharmacokinet* **29**:94–96.
- Fukuda H, Ohashi R, Tsuda-Tsukimoto M, and Tamai I (2008) Effect of plasma protein binding on in vitro-in vivo correlation of biliary excretion of drugs evaluated by sandwich-cultured rat hepatocytes. *Drug Metab Dispos* **36**:1275–1282.
- Gao JW, Peng ZH, Li XY, Sun B, Guo YK, and Liu GL (2011) Simultaneous determination of mycophenolic acid and its metabolites by HPLC and pharmacokinetic studies in rat plasma and bile. *Arch Pharm Res* **34**:59–69.
- Gilibili RR, Chatterjee S, Bagul P, Mosure KW, Murali BV, Mariappan TT, Mandlekar S, and Lai Y (2017) Coproporphyrin-I: a fluorescent, endogenous optimal probe substrate for ABCG2 (MRP2) suitable for vesicle-based MRP2 inhibition assay. *Drug Metab Dispos* **45**:604–611.
- Gill KL, Houston JB, and Galetin A (2012) Characterization of in vitro glucuronidation clearance of a range of drugs in human kidney microsomes: comparison with liver and intestinal glucuronidation and impact of albumin. *Drug Metab Dispos* **40**:825–835.
- Grime K and Paine SW (2013) Species differences in biliary clearance and possible relevance of hepatic uptake and efflux transporters involvement. *Drug Metab Dispos* **41**:372–378.
- Guo C, Yang K, Brouwer KR, St Claire RL, III, and Brouwer KL (2016) Prediction of altered bile acid disposition due to inhibition of multiple transporters: an integrated approach using sandwich-cultured hepatocytes, mechanistic modeling, and simulation. *J Pharmacol Exp Ther* **358**:324–333.
- Haddock RE, Johnson AM, Langley PF, Nelson DR, Pope JA, Thomas DR, and Woods FR (1989) Metabolic pathway of paroxetine in animals and man and the comparative pharmacological properties of its metabolites. *Acta Psychiatr Scand Suppl* **350**:24–26.
- Hesselink DA, van Hest RM, Mathot RA, Bonthuis F, Weimar W, de Bruin RW, and van Gelder T (2005) Cyclosporine interacts with mycophenolic acid by inhibiting the multidrug resistance-associated protein 2. *Am J Transplant* **5**:987–994.
- Hewitt NJ, Lechón MJ, Houston JB, Hallifax D, Brown HS, Maurel P, Kenna JG, Gustavsson L, Lohmann C, Skonberg C, et al. (2007) Primary hepatocytes: current understanding of the regulation of metabolic enzymes and transporter proteins, and pharmaceutical practice for the use of hepatocytes in metabolism, enzyme induction, transporter, clearance, and hepatotoxicity studies. *Drug Metab Rev* **39**:159–234.
- Hillgren KM, Keppler D, Zur AA, Giacomini KM, Stieger B, Cass CE, and Zhang L; International Transporter Consortium (2013) Emerging transporters of clinical importance: an update from the International Transporter Consortium. *Clin Pharmacol Ther* **94**:52–63.
- Hirohashi T, Suzuki H, and Sugiyama Y (1999) Characterization of the transport properties of cloned rat multidrug resistance-associated protein 3 (MRP3). *J Biol Chem* **274**:15181–15185.
- Hirohashi T, Suzuki H, Takikawa H, and Sugiyama Y (2000) ATP-dependent transport of bile salts by rat multidrug resistance-associated protein 3 (Mrp3). *J Biol Chem* **275**:2905–2910.
- Hoffmaster KA, Zamek-Gliszczynski MJ, Pollack GM, and Brouwer KL (2005) Multiple transport systems mediate the hepatic uptake and biliary excretion of the metabolically stable opioid peptide [D-penicillamine-2,5]enkephalin. *Drug Metab Dispos* **33**:287–293.
- Hoshino Y, Fujita D, Nakanishi T, and Tamai I (2016) Molecular localization and characterization of multiple binding sites of organic anion transporting polypeptide 2B1 (OATP2B1) as the mechanism for substrate and modulator dependent drug–drug interaction. *Med Chem Comm* **7**:1775–1782.
- Houle R, Raoul J, Lévesque JF, Pang KS, Nicoll-Griffith DA, and Silva JM (2003) Retention of transporter activities in cryopreserved, isolated rat hepatocytes. *Drug Metab Dispos* **31**:447–451.
- Huang SM, Abernethy DR, Wang Y, Zhao P, and Zineh I (2013) The utility of modeling and simulation in drug development and regulatory review. *J Pharm Sci* **102**:2912–2923.
- ICH (2009) Guidance on nonclinical safety studies for the conduct of human clinical trials and marketing authorization for pharmaceuticals M3 (R2). International Council on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. https://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Multidisciplinary/M3_R2/Step4/M3_R2_Guideline.pdf
- Ishida K, Ullah M, Toth B, Juhasz V, and Unadkat JD (2018) Successful prediction of in vivo hepatobiliary clearances and hepatic concentrations of rosvastatin using sandwich-cultured rat hepatocytes, transporter-expressing cell lines, and quantitative proteomics. *Drug Metab Dispos* **46**:66–74.
- Jacobsen JK, Jensen B, Skonberg C, Hansen SH, and Badolo L (2011) Time-course activities of Oct1, Mrp3, and cytochrome P450s in cultures of cryopreserved rat hepatocytes. *Eur J Pharm Sci* **44**:427–436.
- Jansen PL, Peters WH, and Lamers WH (1985) Hereditary chronic conjugated hyperbilirubinemia in mutant rats caused by defective hepatic anion transport. *Hepatology* **5**:573–579.
- Jørgensen L, Van Beek J, Lund S, Schousboe A, and Badolo L (2007) Evidence of Oatp and Mdr1 in cryopreserved rat hepatocytes. *Eur J Pharm Sci* **30**:181–189.
- Kamisako T, Leier I, Cui Y, König J, Buchholz U, Hummel-Eisenbeiss J, and Keppler D (1999) Transport of monoglucuronosyl and bisglucuronosyl bilirubin by recombinant human and rat multidrug resistance protein 2. *Hepatology* **30**:485–490.
- Kato Y, Takahara S, Kato S, Kubo Y, Sai Y, Tamai I, Yabuuchi H, and Tsuji A (2008) Involvement of multidrug resistance-associated protein 2 (Abcc2) in molecular weight-dependent biliary excretion of beta-lactam antibiotics. *Drug Metab Dispos* **36**:1088–1096.
- Kaye CM, Haddock RE, Langley PF, Mellows G, Tasker TC, Zussman BD, and Greb WH (1989) A review of the metabolism and pharmacokinetics of paroxetine in man. *Acta Psychiatr Scand Suppl* **350**:60–75.
- Kemp CD, Zamek-Gliszczynski MJ, and Brouwer KL (2005) Xenobiotics inhibit hepatic uptake and biliary excretion of taurocholate in rat hepatocytes. *Toxicol Sci* **83**:207–214.
- Kennedy T (1997) Managing the drug discovery/development interface. *Drug Discov Today* **2**:436–444.
- Keppler D (2014) The roles of MRP2, MRP3, OATP1B1, and OATP1B3 in conjugated hyperbilirubinemia. *Drug Metab Dispos* **42**:561–565.
- Kern A, Bader A, Pichlmayr R, and Sewing KF (1997) Drug metabolism in hepatocyte sandwich cultures of rats and humans. *Biochem Pharmacol* **54**:761–772.
- Kienhuis AS, Wortelboer HM, Maas WJ, van Herwijnen M, Kleinjans JC, van Delft JH, and Stierum RH (2007) A sandwich-cultured rat hepatocyte system with increased metabolic competence evaluated by gene expression profiling. *Toxicol In Vitro* **21**:892–901.
- Kilford PJ, Stringer R, Sohal B, Houston JB, and Galetin A (2009) Prediction of drug clearance by glucuronidation from in vitro data: use of combined cytochrome P450 and UDP-glucuronosyltransferase cofactors in alamethicin-activated human liver microsomes. *Drug Metab Dispos* **37**:82–89.
- Kotani N, Maeda K, Watanabe T, Hiramatsu M, Gong LK, Bi YA, Takezawa T, Kusuhaara H, and Sugiyama Y (2011) Culture period-dependent changes in the uptake of transporter substrates in sandwich-cultured rat and human hepatocytes. *Drug Metab Dispos* **39**:1503–1510.
- Lau YY, Sapidou E, Cui X, White RE, and Cheng KC (2002) Development of a novel in vitro model to predict hepatic clearance using fresh, cryopreserved, and sandwich-cultured hepatocytes. *Drug Metab Dispos* **30**:1446–1454.
- LeCluyse E, Bullock P, Madan A, Carroll K, and Parkinson A (1999) Influence of extracellular matrix overlay and medium formulation on the induction of cytochrome P-450 2B enzymes in primary cultures of rat hepatocytes. *Drug Metab Dispos* **27**:909–915.
- LeCluyse EL, Audus KL, and Hochman JH (1994) Formation of extensive canalicular networks by rat hepatocytes cultured in collagen-sandwich configuration. *Am J Physiol* **266**:C1764–C1774.
- Lee JK, Marion TL, Abe K, Lim C, Pollock GM, and Brouwer KL (2010) Hepatobiliary disposition of troglitazone and metabolites in rat and human sandwich-cultured hepatocytes: use of Monte Carlo simulations to assess the impact of changes in biliary excretion on troglitazone sulfate accumulation. *J Pharmacol Exp Ther* **332**:26–34.
- Lengyel G, Veres Z, Szabó P, Vereczkey L, and Jemnitz K (2005) Canalicular and sinusoidal disposition of bilirubin mono- and diglucuronides in sandwich-cultured human and rat primary hepatocytes. *Drug Metab Dispos* **33**:1355–1360.
- Li Y, Hafey MJ, Duong H, Evers R, Cheon K, Holder DJ, Galijatovic-Idrizbegovic A, Sistare FD, and Glaab WE (2017) Antibiotic-induced elevations of plasma bile acids in rats independent of Bsep inhibition. *Toxicol Sci* **157**:30–40.
- Liu L, Cui Y, Chung AY, Shitara Y, Sugiyama Y, Keppler D, and Pang KS (2006) Vectorial transport of enalapril by Oatp1a1/Mrp2 and OATP1B1 and OATP1B3/MRP2 in rat and human livers. *J Pharmacol Exp Ther* **318**:395–402.

- Liu Y, She M, Wu Z, and Dai R (2011) The inhibition study of human UDP-glucuronosyltransferases with cytochrome P450 selective substrates and inhibitors. *J Enzyme Inhib Med Chem* **26**:386–393.
- Lundquist P, Löf J, Sohlenius-Sternbeck AK, Floby E, Johansson J, Bylund J, Hoogstraate J, Afzelius L, and Andersson TB (2014) The impact of solute carrier (SLC) drug uptake transporter loss in human and rat cryopreserved hepatocytes on clearance predictions. *Drug Metab Dispos* **42**:469–480.
- Marion TL, Perry CH, St Claire RL, III, Yue W, and Brouwer KL (2011) Differential disposition of chenodeoxycholic acid versus taurocholic acid in response to acute troglitazone exposure in rat hepatocytes. *Toxicol Sci* **120**:371–380.
- Matsunaga N, Nunoya K, Okada M, Ogawa M, and Tamai I (2013) Evaluation of hepatic disposition of paroxetine using sandwich-cultured rat and human hepatocytes. *Drug Metab Dispos* **41**:735–743.
- Matsunaga N, Suzuki K, Nakanishi T, Ogawa M, Imawaka H, and Tamai I (2015) Modeling approach for multiple transporters-mediated drug-drug interactions in sandwich-cultured human hepatocytes: effect of cyclosporin A on hepatic disposition of mycophenolic acid phenyl-glucuronide. *Drug Metab Pharmacokinet* **30**:142–148.
- Matsunaga N, Wada S, Nakanishi T, Ikenaga M, Ogawa M, and Tamai I (2014) Mathematical modeling of the in vitro hepatic disposition of mycophenolic acid and its glucuronide in sandwich-cultured human hepatocytes. *Mol Pharm* **11**:568–579.
- McRae MP, Lowe CM, Tian X, Bourdet DL, Ho RH, Leake BF, Kim RB, Brouwer KL, and Kashuba AD (2006) Ritonavir, saquinavir, and efavirenz, but not nevirapine, inhibit bile acid transport in human and rat hepatocytes. *J Pharmacol Exp Ther* **318**:1068–1075.
- Mesa VA, De Vos R, and Fevery J (1997) Elevation of the serum bilirubin diconjugate fraction provides an early marker for cholestasis in the rat. *J Hepatol* **27**:912–916.
- Meyers M, Slikker W, Pascoe G, and Vore M (1980) Characterization of cholestasis induced by estradiol-17 beta-D-glucuronide in the rat. *J Pharmacol Exp Ther* **214**:87–93.
- Meyers M, Slikker W, and Vore M (1981) Steroid D-ring glucuronides: characterization of a new class of cholestatic agents in the rat. *J Pharmacol Exp Ther* **218**:63–73.
- Milligan PA, Brown MJ, Marchant B, Martin SW, van der Graaf PH, Benson N, Nucci G, Nichols DJ, Boyd RA, Mandema JW, et al. (2013) Model-based drug development: a rational approach to efficiently accelerate drug development. *Clin Pharmacol Ther* **93**:502–514.
- Naito T, Mino Y, Otsuka A, Ushiyama T, Ito T, Ozono S, Kagawa Y, and Kawakami J (2009) Impact of calcineurin inhibitors on urinary excretion of mycophenolic acid and its glucuronide in kidney transplant recipients. *J Clin Pharmacol* **49**:710–718.
- Nakakariya M, Ono M, Amano N, Moriwaki T, Maeda K, and Sugiyama Y (2012) In vivo biliary clearance should be predicted by intrinsic biliary clearance in sandwich-cultured hepatocytes. *Drug Metab Dispos* **40**:602–609.
- Nakakariya M, Shimada T, Irokawa M, Maeda T, and Tamai I (2008) Identification and species similarity of OATP transporters responsible for hepatic uptake of beta-lactam antibiotics. *Drug Metab Pharmacokinet* **23**:347–355.
- Nakanishi T, Ikenaga M, Fukuda H, Matsunaga N, and Tamai I (2012) Application of quantitative time-lapse imaging (QTLI) for evaluation of MRP2-based drug-drug interaction induced by liver metabolites. *Toxicol Appl Pharmacol* **263**:244–250.
- Nakanishi T, Shibue Y, Fukuyama Y, Yoshida K, Fukuda H, Shirasaka Y, and Tamai I (2011) Quantitative time-lapse imaging-based analysis of drug-drug interaction mediated by hepatobiliary transporter, multidrug resistance-associated protein 2, in sandwich-cultured rat hepatocytes. *Drug Metab Dispos* **39**:984–991.
- Naritomi Y, Terashita S, Kimura S, Suzuki A, Kagayama A, and Sugiyama Y (2001) Prediction of human hepatic clearance from in vivo animal experiments and in vitro metabolic studies with liver microsomes from animals and humans. *Drug Metab Dispos* **29**:1316–1324.
- Noé J, Portmann R, Brun ME, and Funk C (2007) Substrate-dependent drug-drug interactions between gemfibrozil, fluvastatin and other organic anion-transporting peptide (OATP) substrates on OATP1B1, OATP2B1, and OATP1B3. *Drug Metab Dispos* **35**:1308–1314.
- Nozawa T, Minami H, Sugiura S, Tsuji A, and Tamai I (2005) Role of organic anion transporter OATP1B1 (OATP-C) in hepatic uptake of irinotecan and its active metabolite, 7-ethyl-10-hydroxycamptothecin: in vitro evidence and effect of single nucleotide polymorphisms. *Drug Metab Dispos* **33**:434–439.
- Obach RS (1999) Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: an examination of in vitro half-life approach and nonspecific binding to microsomes. *Drug Metab Dispos* **27**:1350–1359.
- Ogimura E, Sekine S, and Horie T (2011) Bile salt export pump inhibitors are associated with bile acid-dependent drug-induced toxicity in sandwich-cultured hepatocytes. *Biochem Biophys Res Commun* **416**:313–317.
- Oorts M, Baze A, Bachelier P, Heyd B, Zacharias T, Annaert P, and Richert L (2016) Drug-induced cholestasis risk assessment in sandwich-cultured human hepatocytes. *Toxicol In Vitro* **34**:179–186.
- Oswald S, König J, Lütjohann D, Giessmann T, Kroemer HK, Rimbach C, Rosskopf D, Fromm MF, and Siegmund W (2008) Disposition of ezetimibe is influenced by polymorphisms of the hepatic uptake carrier OATP1B1. *Pharmacogenet Genomics* **18**:559–568.
- Pang KS, Cherry WF, Terrell JA, and Ulm EH (1984) Disposition of enalapril and its diacid metabolite, enalaprilat, in a perfused rat liver preparation. Presence of a diffusional barrier for enalaprilat into hepatocytes. *Drug Metab Dispos* **12**:309–313.
- Parker AJ and Houston JB (2008) Rate-limiting steps in hepatic drug clearance: comparison of hepatocellular uptake and metabolism with microsomal metabolism of saquinavir, nelfinavir, and ritonavir. *Drug Metab Dispos* **36**:1375–1384.
- Pedersen JM, Matsson P, Bergström CA, Hoogstraate J, Norén A, LeCluyse EL, and Artursson P (2013) Early identification of clinically relevant drug interactions with the human bile salt export pump (BSEP/ABCB11). *Toxicol Sci* **136**:328–343.
- Pfeifer ND, Bridges AS, Ferslew BC, Hardwick RN, and Brouwer KL (2013b) Hepatic basolateral efflux contributes significantly to rosuvastatin disposition II: characterization of hepatic elimination by basolateral, biliary, and metabolic clearance pathways in rat isolated perfused liver. *J Pharmacol Exp Ther* **347**:737–745.
- Pfeifer ND, Yang K, and Brouwer KL (2013a) Hepatic basolateral efflux contributes significantly to rosuvastatin disposition I: characterization of basolateral versus biliary clearance using a novel protocol in sandwich-cultured hepatocytes. *J Pharmacol Exp Ther* **347**:727–736.
- Picard N, Yee SW, Woillard JB, Lebranchu Y, Le Meur Y, Giacomini KM, and Marquet P (2010) The role of organic anion-transporting polypeptides and their common genetic variants in mycophenolic acid pharmacokinetics. *Clin Pharmacol Ther* **87**:100–8.
- Ramsden D, Tweedie DJ, St George R, Chen LZ, and Li Y (2014) Generating an in vitro-in vivo correlation for metabolism and liver enrichment of a hepatitis C virus drug, faldaprevir, using a rat hepatocyte model (HepatoPac). *Drug Metab Dispos* **42**:407–414.
- Rius M, Hummel-Eisenbeiss J, Hofmann AF, and Keppler D (2006) Substrate specificity of human ABCG4 (MRP4)-mediated cotransport of bile acids and reduced glutathione. *Am J Physiol Gastrointest Liver Physiol* **290**:G640–G649.
- Rodrigues AD, Lai Y, Cvijic ME, Elkin LL, Zvyaga T, and Soars MG (2014) Drug-induced perturbations of the bile acid pool, cholestasis, and hepatotoxicity: mechanistic considerations beyond the direct inhibition of the bile salt export pump. *Drug Metab Dispos* **42**:566–574.
- Sharma NS, Nagrath D, and Yarmush ML (2010) Adipocyte-derived basement membrane extract with biological activity: applications in hepatocyte functional augmentation in vitro. *FASEB J* **24**:2364–2374.
- Shen H, Dai J, Liu T, Cheng Y, Chen W, Freeden C, Zhang Y, Humphreys WG, Marathe P, and Lai Y (2016) Coproporphyrins I and III as functional markers of OATP1B activity: in vitro and in vivo evaluation in preclinical species. *J Pharmacol Exp Ther* **357**:382–393.
- Shipkova M, Strassburg CP, Braun F, Streit F, Gröne HJ, Armstrong VW, Tukey RH, Oellerich M, and Wieland E (2001) Glucuronide and glucoside conjugation of mycophenolic acid by human liver, kidney and intestinal microsomes. *Br J Pharmacol* **132**:1027–1034.
- Sieg A, Vavilsky J, Stiehl A, Raedsch R, Czygan P, and Kommerell B (1986) Isomers of bilirubin glucuronide in serum and bile before and after relief of common duct obstruction. *J Hepatol* **3**:341–347.
- Slaus K, Coughtrie MW, Sharp S, Vanhaecke T, Vercauthe A, and Rogiers V (2001) Influence of culture system and medium enrichment on sulfotransferase and sulfatase expression in male rat hepatocyte cultures. *Biochem Pharmacol* **61**:1107–1117.
- Slizgi JR, Lu Y, Brouwer KR, St Claire RL, Freeman KM, Pan M, Brock WJ, and Brouwer KL (2016) Inhibition of human hepatic bile acid transporters by tolvaftan and metabolites: contributing factors to drug-induced liver injury? *Toxicol Sci* **149**:237–250.
- Smak Gregor PJ, van Gelder T, Hesse CJ, van der Mast BJ, van Besouw NM, and Weimar W (1999) Mycophenolic acid plasma concentrations in kidney allograft recipients with or without cyclosporin: a cross-sectional study. *Nephrol Dial Transplant* **14**:706–708.
- Soars MG, Grime K, Sproston JL, Webb PJ, and Rilett RJ (2007) Use of hepatocytes to assess the contribution of hepatic uptake to clearance in vivo. *Drug Metab Dispos* **35**:859–865.
- Staat CE and Tett SE (2007) Clinical pharmacokinetics and pharmacodynamics of mycophenolate in solid organ transplant recipients. *Clin Pharmacokinet* **46**:13–58.
- Tagliacozzi D, Mozzi AF, Casetta B, Bertucci P, Bernardini S, Di Ilio C, Urbani A, and Federici G (2003) Quantitative analysis of bile acids in human plasma by liquid chromatography-electrospray tandem mass spectrometry: a simple and rapid one-step method. *Clin Chem Lab Med* **41**:1633–1641.
- Tamai I and Nakanishi T (2013) OATP transporter-mediated drug absorption and interaction. *Curr Opin Pharmacol* **13**:859–863.
- Tamai I, Nozawa T, Koshida M, Nezu J, Sai Y, and Tsuji A (2001) Functional characterization of human organic anion transporting polypeptide B (OATP-B) in comparison with liver-specific OATP-C. *Pharm Res* **18**:1262–1269.
- Thapari EH, Houghton JS, Uyeda C, Grillo MP, and Jin L (2011) Effect of culture time on the basal expression levels of drug transporters in sandwich-cultured primary rat hepatocytes. *Drug Metab Dispos* **39**:2387–2394.
- Tetsuka K, Gerst N, Tamura K, and Masters JN (2014a) Glucuronidation and subsequent biliary excretion of mycophenolic acid in rat sandwich-cultured hepatocytes. *Drug Metab Pharmacokinet* **29**:129–134.
- Tetsuka K, Gerst N, Tamura K, and Masters JN (2014b) Species differences in sinusoidal and canalicular efflux transport of mycophenolic acid 7-O-glucuronide in sandwich-cultured hepatocytes. *Pharmacol Res Perspect* **2**:e00035.
- Tetsuka K, Ohbuchi M, and Tabata K (2017) Recent progress in hepatocyte culture models and their application to the assessment of drug metabolism, transport, and toxicity in drug discovery: the value of tissue engineering for the successful development of a microphysiological system. *J Pharm Sci* **106**:2302–2311.
- Tougou K, Fukuda T, Ito T, Yamazaki H, Fujio Y, and Azuma J (2007) Genetic polymorphism of bile acid CoA:amino acid N-acyltransferase in Japanese individuals. *Drug Metab Pharmacokinet* **22**:125–128.
- Treijtel N, van Helvoort H, Barendregt A, Blaauboer BJ, and van Eijkeren JC (2005) The use of sandwich-cultured rat hepatocytes to determine the intrinsic clearance of compounds with different extraction ratios: 7-ethoxycoumarin and warfarin. *Drug Metab Dispos* **33**:1325–1332.
- Turncliff RZ, Hoffmaster KA, Kalvas JC, Pollack GM, and Brouwer KL (2006) Hepatobiliary disposition of a drug/metabolite pair: comprehensive pharmacokinetic modeling in sandwich-cultured rat hepatocytes. *J Pharmacol Exp Ther* **318**:881–889.
- Tuschl G, Hrach J, Walter Y, Hewitt PG, and Mueller SO (2009) Serum-free collagen sandwich cultures of adult rat hepatocytes maintain liver-like properties long term: a valuable model for in vitro toxicity and drug-drug interaction studies. *Chem Biol Interact* **181**:124–137.
- Tzvetkov MV, dos Santos Pereira JN, Meineke I, Saadatmand AR, Stingl JC, and Brockmöller J (2013) Morphine is a substrate of the organic cation transporter OCT1 and polymorphisms in OCT1 gene affect morphine pharmacokinetics after codeine administration. *Biochem Pharmacol* **86**:666–678.
- van de Steeg E, Stránecký V, Hartmannová H, Nosková L, Hřebíček M, Wagenaar E, van Esch A, de Waart DR, Oude Elferink RP, Kenworthy KE, et al. (2012) Complete OATP1B1 and OATP1B3 deficiency causes human Rotor syndrome by interrupting conjugated bilirubin reuptake into the liver. *J Clin Invest* **122**:519–528.
- Van Steenberghe W and Fevery J (1990) Effects of uridine diphosphate glucuronosyltransferase activity on the maximal secretion rate of bilirubin conjugates in the rat. *Gastroenterology* **99**:488–499.
- Varma MV and El-Kattan AF (2016) Transporter-enzyme interplay: deconvoluting effects of hepatic transporters and enzymes on drug disposition using static and dynamic mechanistic models. *J Clin Pharmacol* **56** (Suppl 7):S99–S109.
- Varma MV, Lai Y, Kimoto E, Goosen TC, El-Kattan AF, and Kumar V (2013) Mechanistic modeling to predict the transporter- and enzyme-mediated drug-drug interactions of repaglinide. *Pharm Res* **30**:1188–1199.
- Venkatasubramanian R, Fukuda T, Niu J, Mizuno T, Chidambaram V, Vinks AA, and Sadhasivam S (2014) ABCG3 and OCT1 genotypes influence pharmacokinetics of morphine in children. *Pharmacogenomics* **15**:1297–1309.

- Watanabe T, Kusunohara H, Maeda K, Kanamaru H, Saito Y, Hu Z, and Sugiyama Y (2010) Investigation of the rate-determining process in the hepatic elimination of HMG-CoA reductase inhibitors in rats and humans. *Drug Metab Dispos* **38**:215–222.
- Westley IS, Morris RG, Evans AM, and Sallustio BC (2008) Glucuronidation of mycophenolic acid by Wistar and Mrp2-deficient TR- rat liver microsomes. *Drug Metab Dispos* **36**:46–50.
- Yan GZ, Brouwer KL, Pollack GM, Wang MZ, Tidwell RR, Hall JE, and Paine MF (2011) Mechanisms underlying differences in systemic exposure of structurally similar active metabolites: comparison of two preclinical hepatic models. *J Pharmacol Exp Ther* **337**: 503–512.
- Yan GZ, Generaux CN, Yoon M, Goldsmith RB, Tidwell RR, Hall JE, Olson CA, Clewell HJ, Brouwer KL, and Paine MF (2012) A semiphiologically based pharmacokinetic modeling approach to predict the dose-exposure relationship of an antiparasitic prodrug/active metabolite pair. *Drug Metab Dispos* **40**:6–17.
- Yang K and Brouwer KL (2014) Hepatocellular exposure of troglitazone metabolites in rat sandwich-cultured hepatocytes lacking Bcrp and Mrp2: interplay between formation and excretion. *Drug Metab Dispos* **42**:1219–1226.
- Yang X, Gandhi YA, Duignan DB, and Morris ME (2009) Prediction of biliary excretion in rats and humans using molecular weight and quantitative structure-pharmacokinetic relationships. *AAPS J* **11**:511–525.
- Yau WP, Vathsala A, Lou HX, Zhou S, and Chan E (2009) Mechanism-based enterohepatic circulation model of mycophenolic acid and its glucuronide metabolite: assessment of impact of cyclosporine dose in Asian renal transplant patients. *J Clin Pharmacol* **49**: 684–699.
- Yu H, Bischoff D, and Tweedie D (2010) Challenges and solutions to metabolites in safety testing: impact of the International Conference on Harmonization M3(R2) guidance. *Expert Opin Drug Metab Toxicol* **6**:1539–1549.
- Zamek-Gliszczynski MJ, Xiong H, Patel NJ, Turncliff RZ, Pollack GM, and Brouwer KL (2003) Pharmacokinetics of 5 (and 6)-carboxy-2',7'-dichlorofluorescein and its diacetate promoiety in the liver. *J Pharmacol Exp Ther* **304**:801–809.
- Zhang L, Zhang YD, Strong JM, Reynolds KS, and Huang SM (2008) A regulatory viewpoint on transporter-based drug interactions. *Xenobiotica* **38**:709–724.
- Zhang Y, Han YH, Putluru SP, Matta MK, Kole P, Mandlekar S, Furlong MT, Liu T, Iyer RA, Marathe P, et al. (2016) Diclofenac and its acyl glucuronide: determination of in vivo exposure in human subjects and characterization as human drug transporter substrates in vitro. *Drug Metab Dispos* **44**:320–328.
- Zou P, Liu X, Wong S, Feng MR, and Liederer BM (2013) Comparison of in vitro–in vivo extrapolation of biliary clearance using an empirical scaling factor versus transport-based scaling factors in sandwich-cultured rat hepatocytes. *J Pharm Sci* **102**:2837–2850.

Address correspondence to: Dr. Ikumi Tamai, Department of Membrane Transport and Biopharmaceutics, Faculty of Pharmaceutical Sciences, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, Kakumamachi, Kanazawa 920-1192, Japan. E-mail: tamai@p.kanazawa-u.ac.jp